

Neuland Laboratories Limited

Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113 Road No. 2, Banjara Hills Hyderabad - 500 034. Telangana, India.

Tel: 040 30211600 / 23551081 Fax: 040 30211602 Email: neuland@neulandlabs.com www.neulandlabs.com

October 26, 2018

To B S E Limited Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai - 400 001

Scrip Code: 524558

To The National Stock Exchange of India Ltd Exchange Plaza, Bandra Kurla Complex Bandra (E) Mumbai - 400 001

Scrip Code: NEULANDLAB

Series: EQ

Dear Sirs,

Results Release and Earnings Call Notice

We refer to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015 and enclose a copy of the Q2 FY 2019 Earnings Call details, for your information and records.

Thanking you,

Yours faithfully, For Neuland Laboratories Limited

Sarada Bhamidipati Company Secretary

Encl:a/a



Neuland Laboratories Limited's Q2 FY 2018-19 Results Conference Call At 15:30 hrs. IST on November 2, 2018

Neuland Laboratories Limited will announce its results for the quarter ended September 30, 2018 on November 2, 2018. The results will also be made available on the website of the Company, www.neulandlabs.com.

Following the announcement, the management of the Company will host an Earnings Call on the same day at 15:30 hrs. The details of the earnings call are:

Date: November 2, 2018

Time: 15:30 Hrs.

Dial-in Number: +91 22 6629 0021 / +91 22 7194 5721

You can also click here for the diamond pass and calendar invite to your inbox

Other Numbers:

Local Access Number

+91 70456 71221 (Available all over India)

International Toll-Free Number

USA - 18667462133 | UK - 08081011573 | Singapore - 8001012045 | Hong Kong - 800964448

About Neuland Laboratories Limited (BSE:524558, NSE: NEULANDLAB)

For over 34 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs, and it has filed around 56 U.S. drug master files (USDMFs) and over 650 Regulatory filings in the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the USFDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), Health Canada, CFDA (China) ISO 9001, ISO14001, OHSAS18001 and ISO 27001.

For more information, visit <u>www.NeulandLabs.com</u>.

For Queries:

Neuland: <u>ir@neulandlabs.com</u> or Diwakar Pingle: <u>dpingle@christensenir.com</u>